Australia markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
228.46+6.96 (+3.14%)
As of 11:35AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close221.50
Open225.50
Bid226.02 x 900
Ask226.36 x 900
Day's range217.87 - 233.30
52-week range6.77 - 331.68
Volume1,015,876
Avg. volume5,042,652
Market cap15.366B
Beta (5Y monthly)1.58
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?
    Motley Fool

    Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?

    Johnson & Johnson and Novavax are approaching the finish line in this race. A U.S. Food and Drug Administration (FDA) committee meets today, Feb. 26, to discuss a possible Emergency Use Authorization (EUA) for the Johnson & Johnson candidate. A trial report released this week shows Johnson & Johnson's investigational vaccine fulfilled (and exceeded) efficacy and safety requirements.

  • Is Novavax Stock a Buy?
    Motley Fool

    Is Novavax Stock a Buy?

    Novavax (NASDAQ: NVAX) is one stock that I made the right call on; it's been a huge winner. As far back as March 2018, I wrote that "if you're willing to take on risk, buying a small position in Novavax could pay off in a big way." Throughout 2020, I sang Novavax's praises.

  • Here Are the 2 Most Important Things to Look for in Novavax's Earnings Report Next Week
    Motley Fool

    Here Are the 2 Most Important Things to Look for in Novavax's Earnings Report Next Week

    Novavax doesn't have products on the market yet, which means the biotech company is yet to report an annual profit. Novavax recently reported U.K. phase 3 trial results and just completed enrollment in a U.S. phase 3 trial. Possible regulatory authorizations sit on the horizon.